Why is Caplin Point Lab falling/rising?

As of 26-Sep, Caplin Point Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 2,037.40, which reflects a decrease of Rs 142.95 or 6.56%. The stock has underperformed its sector by 4.22% today and has been on a downward trend for the last two days, accumulating a total loss of 9.93% during this period. Additionally, the stock has touched an intraday low of Rs 2011, indicating significant selling pressure. In terms of performance over various periods, the stock has seen a 1-week decline of 13.10%, a 1-month decrease of 2.31%, and a year-to-date drop of 18.56%, contrasting with a 6.09% gain over the past year. Despite these recent struggles, the company boasts a high management efficiency with a return on equity of 19.84%, a low debt-to-equity ratio, and has reported positive results for the last 12 consecutive quarters.
In the broader market context, the stock's recent performance has been notably weaker than the benchmark, with the Sensex declining only 2.66% over the past week. This underperformance is further highlighted by the pharmaceuticals and drugs sector, which has also fallen by 2.35%. The decline in investor participation, as evidenced by a 14.18% drop in delivery volume compared to the 5-day average, suggests waning interest among retail investors, although institutional investors have slightly increased their stake in the company. This mixed sentiment, combined with the stock's inability to maintain levels above its moving averages, indicates a challenging environment for Caplin Point Laboratories Ltd despite its strong fundamentals and consistent returns over the longer term.